Efficacy and safety of an extended-release formulation of desloratadine and pseudoephedrine vs the individual components in the treatment of seasonal allergic rhinitis

Annals of Allergy, Asthma and Immunology

Volumn 94, Issue 3, 2005, Pages 348-354

  Pleskow, Warren ^a   Grubbe, Robert ^b   Weiss, Steven ^c   Lutsky, Barry ^d  

^a RADIANT RESEARCH   (United States)

^b Center of Research Excellence LLC   (United States)

^c Florida Allergy Asthma Immunology   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; DECONGESTIVE AGENT; DESLORATADINE; PSEUDOEPHEDRINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED DRUG RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HAY FEVER; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NOSE CONGESTION; PRIORITY JOURNAL; RESTLESSNESS; SCHOOL CHILD; SOMNOLENCE; SYMPTOM; TABLET; TACHYCARDIA; XEROSTOMIA;

EID: 15444368515     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60986-6     Document Type: Article

References (25)

1. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol. 1998;81:478-518.
2. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol. 1994;93:413-423.
3. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
4. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc. 1999;20:209-213.
5. Rachelefsky GS. National guidelines needed to manage rhinitis and prevent complications. Ann Allergy Asthma Immunol. 1999;82:296-305.
6. Van Cauwenberg P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy. 2000;55:116-134.
7. 1-receptor antagonists. Allergy. 2000;55(suppl 64): 17-27.
8. Hadley JA. Evaluation and management of allergic rhinitis. Med Clin North Am. 1999;83:13-25.
9. 1-receptor antagonist, in patients with seasonal allergic rhinitis: assessment during the spring and fall allergy seasons. Clin Drug Invest. 2001;21:25-32.
10. Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol. 2001;107:751-762.
11. Affrime M, Gupta S, Banfield C, et al. A pharmacokinetic profile of desloratadine in healthy adults including elderly. Clin Pharmacokinet. 2002;41(suppl 1):13-19.
12. Gupta S, Banfield C, Affrime M, et al. Oral bioavailability of desloratadine is unaffected by food. Clin Pharmacokinet. 2001;41(suppl 1):7-12.
13. Banfield C, Hunt T, Reyderman L, et al. Lack of clinically relevant interaction between desloratadine and erythromycin. Clin Pharmacokinet. 2002;41(suppl 1):29-35.
14. Banfield C, Herren J, Keung A, et al. Desloratadine has no clinically relevant electrocardiographic or pharmacodynamic interactions with ketoconazole. Clin Pharmacokinet. 2002; 41(suppl 1):37-44.
15. Gupta S, Banfield C, Kantesaria B, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther. 2001;23:451-466.
16. Banfield C, Gupta S, Kantesaria B, et al. No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily antihistamine. J Allergy Clin Immunol. 2001;107(suppl):S161.
17. Khalilieh S, Krishna G, Marino M, et al. Lack of an interaction with coadministration of desloratadine and cimetidine. Ann Allergy Asthma Immunol. 2002;88:110.
18. Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy. 2001;56(suppl 65): 14-20.
19. Nayak AS, Schenkel E. Desloratadine reduces nasal congestion in patients with intermittent allergic rhinitis. Allergy. 2001;56:1077-1080.
20. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma [published erratum appears in J Allergy Clin Immunol. 1998;101(pt 1):792]. J Allergy Clin Immunol. 1997;100:781-788.
21. Bronsky E, Boggs P, Findlay S, et al. Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis. J Allergy Clin Immunol. 1995;96:139-147.
22. Roman IJ, Danzig M. Loratadine: a review of recent findings in pharmacology, pharmacokinetics, efficacy, and safety, with a look at its use in combination with pseudoephedrine. Clin Rev Allergy. 1993;11:89-110.
23. Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol. 1999;104:100-106.
24. Bertrand B, Jamart J, Marchal JL, Arendt C. Cetirizine and pseudoephedrine retard alone and in combination in the treatment of perennial allergic rhinitis: a double-blind multicentre study. Rhinology. 1996;34:91-96.
25. Schenkel E, Corren J, Murray JJ. Efficacy of once-daily desloratadine/pseudoephedrine for relief of nasal congestion. Allergy Asthma Proc. 2002;23:325-330.